Joinn Laboratories(China)Co.,Ltd. (603127.SS)
CNY 17.42
(0.87%)
CNY 17.42
(0.87%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.37 Billion CNY | 4.45% |
| 2022 | 2.26 Billion CNY | 49.54% |
| 2021 | 1.51 Billion CNY | 40.97% |
| 2020 | 1.07 Billion CNY | 68.27% |
| 2019 | 639.37 Million CNY | 56.4% |
| 2018 | 408.79 Million CNY | 35.69% |
| 2017 | 301.27 Million CNY | 24.6% |
| 2016 | 241.8 Million CNY | 17.04% |
| 2015 | 206.6 Million CNY | 11.79% |
| 2014 | 184.81 Million CNY | 28.5% |
| 2013 | 143.82 Million CNY | 47.68% |
| 2012 | 97.38 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 322.43 Million CNY | -59.05% |
| 2024 Q3 | 484.28 Million CNY | -7.67% |
| 2024 Q2 | 524.54 Million CNY | 62.68% |
| 2023 Q4 | 787.47 Million CNY | 36.95% |
| 2023 FY | 2.36 Billion CNY | 4.45% |
| 2023 Q1 | 369.38 Million CNY | -62.75% |
| 2023 Q2 | 642.69 Million CNY | 73.99% |
| 2023 Q3 | 575 Million CNY | -10.53% |
| 2022 Q3 | 499.51 Million CNY | -1.26% |
| 2022 Q2 | 505.9 Million CNY | 86.7% |
| 2022 Q1 | 270.97 Million CNY | -58.94% |
| 2022 FY | 2.26 Billion CNY | 49.54% |
| 2022 Q4 | 991.57 Million CNY | 98.51% |
| 2021 Q1 | 200.99 Million CNY | -54.77% |
| 2021 Q3 | 322.24 Million CNY | -3.39% |
| 2021 Q4 | 659.87 Million CNY | 104.77% |
| 2021 FY | 1.51 Billion CNY | 40.97% |
| 2021 Q2 | 333.56 Million CNY | 65.96% |
| 2020 Q3 | 234.15 Million CNY | -3.5% |
| 2020 Q4 | 444.39 Million CNY | 89.78% |
| 2020 FY | 1.07 Billion CNY | 68.27% |
| 2020 Q1 | 154.71 Million CNY | -46.82% |
| 2020 Q2 | 242.64 Million CNY | 56.83% |
| 2019 FY | 639.37 Million CNY | 56.4% |
| 2019 Q4 | 290.92 Million CNY | 97.11% |
| 2019 Q3 | 147.59 Million CNY | 16.72% |
| 2019 Q2 | 126.44 Million CNY | 69.91% |
| 2019 Q1 | 74.41 Million CNY | -54.91% |
| 2018 Q3 | 108.63 Million CNY | 30.12% |
| 2018 Q2 | 83.49 Million CNY | 61.7% |
| 2018 Q4 | 165.03 Million CNY | 51.92% |
| 2018 Q1 | 51.63 Million CNY | -60.74% |
| 2018 FY | 408.79 Million CNY | 35.69% |
| 2017 FY | 301.27 Million CNY | 24.6% |
| 2017 Q1 | 18.93 Million CNY | -84.76% |
| 2017 Q2 | 76.08 Million CNY | 301.8% |
| 2017 Q3 | 74.75 Million CNY | -1.74% |
| 2017 Q4 | 131.5 Million CNY | 75.92% |
| 2016 Q3 | 48.76 Million CNY | 0.0% |
| 2016 Q4 | 124.22 Million CNY | 154.76% |
| 2016 FY | 241.8 Million CNY | 17.04% |
| 2015 FY | 206.6 Million CNY | 11.79% |
| 2014 FY | 184.81 Million CNY | 28.5% |
| 2013 FY | 143.82 Million CNY | 47.68% |
| 2012 FY | 97.38 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 9.14 Billion CNY | 74.02% |
| WuXi AppTec Co., Ltd. | 40.04 Billion CNY | 94.065% |
| Autobio Diagnostics Co., Ltd. | 4.44 Billion CNY | 46.52% |
| Thalys Medical Technology Group Inc. | 2 Billion CNY | -18.461% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 8.53 Billion CNY | 72.171% |
| Chemclin Diagnostics Co., Ltd. | 445.34 Million CNY | -433.633% |